Populations | Trans men (≥ 18 yr) with:
All original breast tissue remaining Some breast tissue removed (i.e., breast reduction) Chest-contouring surgery (e.g., liposculpting, pectoral implants) Trans women (≥ 18 yr) with:
| Asymptomatic trans men (≥ 18 yr) with:
All original breast tissue remaining, with a history of CSH use Some breast tissue removed, with or without a history of CSH use Chest-contouring surgery, with or without a history of CSH use Asymptomatic trans women (≥ 18 yr) with:
Breast augmentation/implants, with a history of CSH use No breast augmentation/implants, with a history of CSH use
| Trans men (≥ 18 yr) with:
All original breast tissue remaining, with or without a history of CSH use Some breast tissue removed, with or without a history of CSH use Chest surgery, with or without a history of CSH use Trans women (≥ 18 yr) with:
Breast augmentation/implants, with or without a history of CSH use No breast augmentation/implants, with or without a history of CSH use
|
Interventions |
Use of masculinizing CSH (e.g., testosterone) for trans men Use of feminizing CSH (e.g., antiandrogen agents, estrogen or progesterone) for trans women
| Breast screening with:
| Breast screening with:
|
Comparators |
|
Trans people not screened for breast cancer No comparison group required (only for cancer detection rate, interval cancer rate, sensitivity, specificity and all harm outcomes)
| NA |
Outcomes |
Breast cancer risk (incidence) Prognosis: stage at diagnosis, node positivity, tumour size, tumour grade, tumour type, survival Breast cancer mortality
|
Benefits: breast-cancer–specific mortality, all-cause mortality, cancer detection rate, interval cancer rate, sensitivity, specificity Harms: overdiagnosis, false-positive screen, patient-reported anxiety, patient-reported pain/discomfort
| Breast screening recommendations for trans people with a focus on:
Eligibility requirements Screening modalities Screening intervals
|
Designs/ document types |
Randomized controlled trials Nonrandomized experimental studies Observational studies with comparison groups
|
Randomized controlled trials Nonrandomized experimental studies Observational studies with or without* comparison groups Diagnostic evaluation studies
|
Guidelines Position statements
|
Other |
Published between Jan. 1, 1997, and May 19, 2017 Peer-reviewed or grey literature Full reports, or conference abstracts and proceedings Published in English
|
Published between Jan. 1, 1997, and May 9, 2017 Peer-reviewed or grey literature Full reports, or conference abstracts and proceedings Published in English
|
Published between Jan. 1, 1997, and Feb. 13, 2017 Peer-reviewed or grey literature Full reports, or conference abstracts and proceedings Published in English
|